CONTROL OF SENSOR/TISSUE INTERACT FOR EXTENDED LIFETIME

控制传感器/组织相互作用以延长使用寿命

• 批准号: 2870410
• 负责人: FRANCIS MOUSSY
• 金额: $ 36.44万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2870410
• 关键词: artificial membranes; bioengineering /biomedical engineering; biological response modifiers; biomaterial development /preparation; biomaterial evaluation; biomaterial interface interaction; biosensor device; blood glucose; copolymer; diabetes mellitus; gel; laboratory rat; microcapsule; microdialysis; monitoring device

DESCRIPTION (Adapted from applicant's abstract): A major obstacle to the wide application of implantable glucose sensors is that the progressively lose function after a relatively short period of time in vivo. This is a result of tissue responses such as inflammation and fibrosis with resulting loss of vasculature as well as degradation of the sensor. Although our current Nafion-based glucose sensor displayed excellent stability in vitro, it rapidly calcified and degraded in vivo. The investigator hypothesizes that in vivo sensor performance can be enhanced by developing new membranes and by controlling the tissue interface by suppressing inflammation and fibrosis as well as increasing neovascularization. Aim 1 will develop new membranes to replace Nafion, and also to develop novel surface hydrogels with tissue response modifiers (TRM's) to control fibrosis, inflammation, and neovascularization. Aim 2 will develop biodegradable TRM delivery systems to control inflammation, fibrosis and neovascularization. Aim 3 will evaluate in vitro and in vivo (rats), the developed sensors and components to determine performance, including life span.

描述（改编自申请人的摘要）： 广泛的可植入葡萄糖传感器的应用是逐渐 在体内相对较短的时间后丢失功能。 这是一个 组织反应（例如炎症和纤维化）的结果 脉管系统的丧失以及传感器的降解。 虽然我们的 当前基于Nafion的葡萄糖传感器在体外表现出极好的稳定性， 它迅速钙化并在体内降解。 研究人员假设 可以通过开发新膜来增强体内传感器性能 并通过抑制炎症和 纤维化以及增加新生血管形成。 AIM 1将发展新的 膜以取代Nafion，并发展出新型的表面水凝胶 使用组织反应修饰符（TRM）来控制纤维化，炎症， 和新血管形成。 AIM 2将发展可生物降解的TRM交付 控制炎症，纤维化和新血管形成的系统。 目标3 将评估体外和体内（大鼠），开发的传感器和 确定性能的组件，包括寿命。